When it comes to uncovering how the brain develops across the human lifespan, "change" may be the key word. Mounting evidence from molecular atlases of brain development suggests that the midgestational human brain markedly differs from the adult brain, undergoing wholesale transformation over time by tuning the timing and location of gene expression (1). "In fact, so many genes are translated differently in the fetal brain, the fetal brain at a molecular level could almost be considered a different organ," notes Thomas Insel, director of the National Institute of Mental Health in Bethesda, Maryland (2). Environmental cues and experience might influence gene expression during development through mechanisms yet to be defined with the precision that has long characterized studies of gene regulation. To the extent that epigenetics has come to represent a field of active inquiry, it now appears that a comprehensive understanding of brain development, function, and evolution depends on tools to probe how agents of epigenetic change, such as methylation and histone modifications, might contribute to behavioral change. To that end, a group of neuroscientists and molecular biologists convened in March 2014 for the Arthur M. Sackler colloquium Epigenetic Changes in the Developing Brain: Effects on Behavior at the National Academy of Sciences in Washington, DC. At the colloquium, Insel, who has long espoused a scientific approach to the prevention and treatment of mental disorders, shared his views on the growing importance of epigenetics to neuroscience. PNAS asked Insel for his thoughts on a few highlights from the event.
PNAS: Compared with many other organs, the human brain is still largely shrouded in mystery. To underscore the scope of the challenge facing neuroscientists, you recounted in your talk titled Brain Exceptionalism that the adult human brain, which claims onefifth of the oxygen individuals consume, contains around 86 billion neurons, which divide hundreds of thousands of times per minute during development and form trillions of synapses. Does the brain pose particular challenges for epigenetic studies?
Insel: I chose that title for my talk with particular reference to epigenetics because it appears that the way in which epigenetic marks-at least methylation-occur in the brain might follow a different set of rules than in other parts of the body. We heard some evidence for that difference during the colloquium; in particular, Joseph Ecker [of the Salk Institute] presented data on non-CG methylation in the brain as an example of noncanonical epigenetic regulation. Ecker also suggested that epigenetic signatures could be used to classify cell types in the brain. It would be tremendously useful, for example, if we could classify all of the cells that we now call pyramidal neurons or inhibitory neurons into subtypes. Once we have such tools, we can begin to assemble a parts-list for the human brain. Without a well-defined taxonomy of the human brain, it is difficult to truly understand epigenetics in the brain.
PNAS:
The dialogue between neuroscientists and molecular biologists has gained momentum in recent years. Why do you think the human genomics revolution took longer to encompass neuroscience, compared with some other areas of biology?
Insel: Part of the problem in performing detailed molecular analysis of the human brain is practical: You can biopsy many other organs and tissues easily, but it is difficult to obtain human brain tissue for analysis. Observations from the field of behavioraland to some extent developmental-neuroscience suggest that epigenetics might provide a molecular handle on the link between early life experience and enduring behavioral consequences. Which is why it is essential to encourage dialogue between behavioral and developmental neuroscientists and molecular biologists, who have a mechanistic understanding of transcriptional regulation. I think that was a major impetus for the colloquium.
PNAS: Among the findings presented at the colloquium-on mechanisms of epigenetic regulation of gene expression, the effects of the environment and experience on the brain, and the potential clinical applications of epigenetics-which surprised you the most?
Insel: I thought the work of Harrison Gabel [of Harvard Medical School] was very surprising; the idea that the length of a gene could be important for understanding its regulation. I had no idea that long genes are expressed preferentially in the brain or that they were preferentially involved in some neurodevelopmental disorders. I also thought the work of John Rinn [of the Broad Institute], showing that long noncoding RNAs are important in brain function and potentially influence behavior, was tremendously important. I say that because the fad now is to do whole exome sequencing [a sequencing technique that targets protein-coding genes], which will not detect long noncoding RNAs. So his work pointed out that we might be overlooking an important player in individual variation as it relates to disease risk or resilience. Andrew Chess [of Mount Sinai Hospital] gave an excellent talk on the tissue specificity of DNA methylation and how different SNPs can influence methylation. PNAS: Tim Bestor of Columbia University opened the colloquium with a cautionary note: Given that sequence data fail to support a directional link between DNA methylation and transcriptional repression in several cases, it is quite difficult, Bestor observed, to establish correlation between DNA methylation and gene silencing, with the exception of situations, such as transposon silencing, genomic imprinting, and X-inactivation. Lest we confound cause and effect, Bestor urged caution against a simplistic view of the gene methylation-transcription link. Is the skepticism about the role of environmental signals in altering gene expression through methylation changes justified?
Insel: This is the 800-pound gorilla that we must grapple with. As Tim Bestor pointed out, we need to be particularly careful about taking a candidate-gene approach to epigenetics. In the past, researchers have often looked for methylation changes in one part of a gene in one heterogeneous group of cells in the nervous system following a behavioral challenge, like stress. That may be like looking for one snowflake in a blizzard. Often, there are so many epigenetic changes occurring simultaneously under a given condition that which ones matter remains an empirical question. To answer the question, we first need a functional readout-in terms of expression-for individual changes at a given site in the genome. Secondly, we need to experimentally demonstrate the effects of manipulating methylation, not just by behavioral intervention but by perturbing methylation itself. We don't have the tools yet to perform the kind of "epigenomic pharmacology" that will allow us to, say, move methyl marks around in the genome and rigorously probe the effects of such changes.
PNAS: Do you think such manipulations will become routine in the foreseeable future?
Insel: I do. Not so much for therapeutic purposes in humans, but as an experimental tool, such interventions are not far off. Recent reports of genomic editing with highly precise targeting of epigenetic marks suggest that such tools will become increasingly common. The field sorely needs such tools because using germ-line knockouts to I feel strongly that the field must go from being descriptive to experimental. To become experimental, we need to develop tools to perturb epigenomic marks.
determine the consequences of epigenetic marks is a cumbersome approach to answer a specific, targeted question.
PNAS: Now that big-data epigenome projects are generating copious information on epigenetics-we heard quite a bit about the results of such efforts at the colloquiumwhat do we need in order to draw links between brain disorders and early life and adult experience?
Insel: I feel strongly that the field must go from being descriptive to experimental and, of course, beyond candidate genes to wholegenome approaches. To become experimental, we need to develop tools to perturb epigenomic marks, as I previously noted. In terms of datasets needed, we must be able to identify through studies in model organisms the functional circuits and cells of interest that need to be targeted for human epigenetic studies. We also need to ensure that negative data from studies that failed to replicate reported effects are published and incorporated into databases.
PNAS: Retrotransposition in the germ line, we heard at the colloquium, might lead to increased genetic diversity at the species level over evolutionary timescales. In what ways might mobile genetic elements be considered an epigenetic force? Do you think somatic variation might similarly drive phenotypic diversity within a species through mechanisms as yet unimagined?
Insel: It is a great question for which we just don't have a precise answer. If somatic variation does enter the germ line, it is not clear how except via structural variants that develop in the egg or sperm. Could environmental effects on egg and sperm confer a Lamarckian influence on subsequent generations? We don't know for certain at this point, but there are several laboratories chasing intergenerational effects. What is fascinating about somatic variation for neuroscientists is that you could have localized changes in the brain, with profound effects that would not be evident in the germ line. The evidence is beginning to accumulate that some of these somatic changes might underlie neurodevelopmental syndromes, and the only way to detect such changes would be to look in individual neurons (3).
